Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT.

Br J Cancer. 2019 May;120(10):975-981. doi: 10.1038/s41416-019-0452-3. Epub 2019 Apr 17.

2.

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P.

Neuro Oncol. 2018 Nov 12;20(12):1634-1642. doi: 10.1093/neuonc/noy078.

3.

Mechanical wear and oxidative degradation analysis of retrieved ultra high molecular weight polyethylene acetabular cups.

Choudhury D, Ranuša M, Fleming RA, Vrbka M, Křupka I, Teeter MG, Goss J, Zou M.

J Mech Behav Biomed Mater. 2018 Mar;79:314-323. doi: 10.1016/j.jmbbm.2018.01.003. Epub 2018 Jan 6.

PMID:
29353775
4.

Diamond-like carbon coatings with zirconium-containing interlayers for orthopedic implants.

Choudhury D, Lackner J, Fleming RA, Goss J, Chen J, Zou M.

J Mech Behav Biomed Mater. 2017 Apr;68:51-61. doi: 10.1016/j.jmbbm.2017.01.023. Epub 2017 Jan 20.

PMID:
28152443
5.

Lagged cumulative spruce budworm defoliation affects the risk of fire ignition in Ontario, Canada.

James PM, Robert LE, Wotton BM, Martell DL, Fleming RA.

Ecol Appl. 2017 Mar;27(2):532-544. doi: 10.1002/eap.1463. Epub 2017 Feb 22.

PMID:
27809401
6.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
7.

A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

Dennie TW, Fleming RA, Bowen CJ, Dar MM, Alberti D, Oliver K, Loconte N, Mulkerin D, Holen KD.

Clin Colorectal Cancer. 2011 Mar 1;10(1):57-62. doi: 10.3816/CCC.2011.n.008.

PMID:
21609937
8.

Broadband cluster transducer for underwater acoustics applications.

Fleming RA, Jones DF, Reithmeier CG.

J Acoust Soc Am. 2009 Nov;126(5):2285-93. doi: 10.1121/1.3216911.

PMID:
19894810
9.

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.

Burris HA 3rd, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, Wilding G.

Clin Cancer Res. 2009 Nov 1;15(21):6702-8. doi: 10.1158/1078-0432.CCR-09-0369. Epub 2009 Oct 13.

10.

A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.

Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK.

Clin Cancer Res. 2008 Jul 15;14(14):4484-90. doi: 10.1158/1078-0432.CCR-07-4417.

11.

Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

LoRusso PM, Jones SF, Koch KM, Arya N, Fleming RA, Loftiss J, Pandite L, Gadgeel S, Weber BL, Burris HA 3rd.

J Clin Oncol. 2008 Jun 20;26(18):3051-6. doi: 10.1200/JCO.2007.14.9633.

PMID:
18565892
12.

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd.

J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19.

PMID:
18490651
13.

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

Midgley RS, Kerr DJ, Flaherty KT, Stevenson JP, Pratap SE, Koch KM, Smith DA, Versola M, Fleming RA, Ward C, O'Dwyer PJ, Middleton MR.

Ann Oncol. 2007 Dec;18(12):2025-9. Epub 2007 Sep 9.

PMID:
17846021
14.

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

Chu QS, Schwartz G, de Bono J, Smith DA, Koch KM, Versola MJ, Pandite L, Arya N, Curtright J, Fleming RA, Ho PT, Rowinsky EK.

J Clin Oncol. 2007 Aug 20;25(24):3753-8.

PMID:
17704424
15.

An economic evaluation of livestock odor regulation distances.

Bazen EF, Fleming RA.

J Environ Qual. 2004 Nov-Dec;33(6):1997-2006.

PMID:
15537921
16.

Synthesis and evaluation of a novel synthetic phosphocholine lipid-AZT conjugate that double-targets wild-type and drug resistant variants of HIV.

Kucera LS, Morris-Natschke SL, Ishaq KS, Hes J, Iyer N, Furman PA, Fleming RA.

Nucleosides Nucleotides Nucleic Acids. 2004;23(1-2):385-99.

PMID:
15043162
17.

Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma.

Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA.

Ann Surg Oncol. 2004 Feb;11(2):178-86.

PMID:
14761921
18.

Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside.

Alexander RL, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL.

J Med Chem. 2003 Sep 11;46(19):4205-8.

PMID:
12954073
19.

Clinical and pathological features of intracranial chordoma with orbital involvement in a child.

Fleming RA, Wilson MW, Fuller CE, Fleming JC, Haik BG.

Ophthalmic Plast Reconstr Surg. 2003 May;19(3):240-2.

PMID:
12918563
20.

Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA.

Ann Surg Oncol. 2003 Mar;10(2):155-62.

PMID:
12620911
21.

Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP.

Pharmacogenetics. 2002 Jan;12(1):31-7.

PMID:
11773862
22.

Prospective trial for the treatment of malignant peritoneal mesothelioma.

Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA.

Am Surg. 2001 Oct;67(10):999-1003.

PMID:
11603562
23.

Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.

Jackson SL, Fleming RA, Loggie BW, Geisinger KR.

Mod Pathol. 2001 Jul;14(7):664-71.

24.

Cellular metabolism in lymphocytes of a novel thioether-phospholipid-AZT conjugate with anti-HIV-1 activity.

Kucera GL, Goff CL, Iyer N, Morris-Natschke S, Ishaq KS, Wyrick SD, Fleming RA, Kucera LS.

Antiviral Res. 2001 May;50(2):129-37.

PMID:
11369433
25.

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.

McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD.

Eur J Surg Oncol. 2001 Feb;27(1):65-73.

PMID:
11237495
26.

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin.

Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR.

Am Surg. 2000 Jun;66(6):561-8.

PMID:
10888132
27.

Effect of childhood and adolescent ultraviolet exposures on cumulative exposure in South East Queensland schools.

Parisi AV, Meldrum LR, Wong JC, Aitken J, Fleming RA.

Photodermatol Photoimmunol Photomed. 2000 Feb;16(1):19-24.

PMID:
10721860
28.

Lifetime ultraviolet exposure estimates for selected population groups in south-east Queensland.

Parisi AV, Meldrum LR, Wong JC, Aitken J, Fleming RA.

Phys Med Biol. 1999 Dec;44(12):2947-53.

PMID:
10616147
29.

Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

Perry JJ, Fleming RA, Rocco MV, Petros WP, Bleyer AJ, Radford JE Jr, Powell BL, Hurd DD.

Bone Marrow Transplant. 1999 Apr;23(8):839-42.

30.

Stability of lorazepam 1 and 2 mg/mL in glass bottles and polypropylene syringes.

Share MJ, Harrison RD, Folstad J, Fleming RA.

Am J Health Syst Pharm. 1998 Oct 1;55(19):2013-5. No abstract available.

PMID:
9784790
31.

An overview of cyclophosphamide and ifosfamide pharmacology.

Fleming RA.

Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S. Review.

PMID:
9322882
32.

Direct comparison of arbutamine and dobutamine stress testing with myocardial perfusion imaging and echocardiography in patients with coronary artery disease.

Shehata AR, Ahlberg AW, Gillam LD, Mascitelli VA, Piriz JM, Fleming RA, Chen C, Waters DD, Heller GV.

Am J Cardiol. 1997 Sep 15;80(6):716-20.

PMID:
9315575
33.

Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma.

Loggie BW, Fleming RA, Hosseinian AA.

Urology. 1997 Sep;50(3):446-8.

PMID:
9301716
34.

Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery.

Chen MY, Chiles C, Loggie BW, Choplin RH, Perini MA, Fleming RA.

J Surg Oncol. 1997 Sep;66(1):19-23.

PMID:
9290688
35.

An estimate of the total UV-B exposure for outdoor workers during a south-east Queensland summer.

Airey DK, Wong JC, Fleming RA, Meldrum LR.

Health Phys. 1997 Apr;72(4):544-9.

PMID:
9119678
36.

Stability of amphotericin B 0.05 and 0.5 mg/mL in 20% fat emulsion.

Owens D, Fleming RA, Restino MS, Cruz JM, Hurd DD.

Am J Health Syst Pharm. 1997 Mar 15;54(6):683-6. No abstract available.

PMID:
9075499
37.
38.

Fast measurements of transmission of erythema effective irradiance through clothing fabrics.

Zhang Z, Thomas BW, Wong CF, Fleming RA.

Health Phys. 1997 Feb;72(2):256-60.

PMID:
9003710
39.

Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.

Loggie BW, Fleming RA, Geisinger KR.

Acta Cytol. 1996 Nov-Dec;40(6):1154-8.

PMID:
8960022
40.

Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.

Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.

Clin Cancer Res. 1996 Jul;2(7):1107-14.

41.

Annual reduction of solar UV exposure to the facial area of outdoor workers in Southeast Queensland by wearing a hat.

Wong JC, Airey DK, Fleming RA.

Photodermatol Photoimmunol Photomed. 1996 Jun;12(3):131-5.

PMID:
8956363
42.

The effects of body size and orientation on ultraviolet radiation exposure.

Parisi AV, Kimlin MG, Wong JC, Fleming RA.

Photodermatol Photoimmunol Photomed. 1996 Apr;12(2):66-72.

PMID:
8897591
43.

Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.

Fleming RA, Cruz JM, Webb CD, Kucera GL, Perry JJ, Hurd DD.

Bone Marrow Transplant. 1996 Apr;17(4):497-501.

PMID:
8722345
44.

Complications of heated intraperitioneal chemotherapy and strategies for prevention.

Loggie BW, Fleming RA.

Cancer Treat Res. 1996;82:221-33.

PMID:
8849953
45.

A comparison of human- and headform-based measurements of solar ultraviolet B dose.

Airey DK, Wong JC, Fleming RA.

Photodermatol Photoimmunol Photomed. 1995 Aug;11(4):155-8.

PMID:
8850248
46.

Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions.

Fleming RA, Olsen DJ, Savage PD, Fox JL.

Am J Health Syst Pharm. 1995 Mar 1;52(5):514-6. No abstract available.

PMID:
7606557
47.

UV-B radiometry and dosimetry for solar measurements.

Wong CF, Toomey S, Fleming RA, Thomas BW.

Health Phys. 1995 Feb;68(2):175-84.

PMID:
7814251
48.

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.

Fleming RA, Capizzi RL, Rosner GL, Oliver LK, Smith SJ, Schiffer CA, Silver RT, Peterson BA, Weiss RB, Omura GA, et al.

Cancer Chemother Pharmacol. 1995;36(5):425-30.

PMID:
7634384
49.

Dihydropyrimidine dehydrogenase activity in cancer patients.

Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renée N, Schneider M, Demard F.

Eur J Cancer. 1993;29A(5):740-4.

PMID:
8471333
50.

General aspects of cancer chemotherapy in the aged.

Fleming RA, Capizzi RL.

Adv Exp Med Biol. 1993;330:271-86. Review. No abstract available.

PMID:
8368138

Supplemental Content

Loading ...
Support Center